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Abstract 
Everolimus is an orally administered mTOR inhibitor. The effect, and mechanism of 
action, of everolimus on lung cancers with an epidermal growth factor receptor (EGFR) 
mutation remain unclear. Four gefitinib-sensitive and -resistant cell lines were used in 
the present work. Growth inhibition was determined using the MTT assay. Transgenic 
mice carrying the EGFR L858R mutation were treated with everolimus (10 mg/kg/day), 
or vehicle alone, from 5 to 20 weeks of age, and were then sacrificed. To evaluate the 
efficacy of everolimus in prolonging survival, everolimus (10 mg/kg/day) or vehicle 
was administered from 5 weeks of age. The four cell lines were similarly sensitive to 
everolimus. Expression of phosphorylated (p) mTOR and pS6 were suppressed upon 
treatment with everolimus in vitro, whereas the pAKT level increased. The numbers of 
lung tumors with a long axis exceeding 1 mm in the everolimus-treated and control 
groups were 1.9 ± 0.9 and 9.4 ± 3.2 (t-test, p<0.001), respectively. pS6 was suppressed 
during everolimus treatment. Although apoptosis and autophagy were not induced in 
everolimus-treated EGFR transgenic mice, angiogenesis was suppressed. The median 
survival time in the everolimus-treated group (58.0 weeks) was significantly longer than 
that in the control group (31.2 weeks) (logrank test, p<0.001). These findings suggest 
that everolimus had an indirect effect on tumor formation by inhibiting angiogenesis 
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and might be effective to treat lung tumors induced by an activating EGFR gene 
mutation.  
 4 
Highlights 
 Everolimus was similarly efficacious, in vitro, on cells harboring various EGFR 
mutations. 
 Everolimus suppressed lung tumors in transgenic mice expressing the L858R 
mutation of EGFR and prolonged the overall survival of these mice. 
 Everolimus might be effective for EGFR-mutated lung cancer by the inhibiting 
tumor angiogenesis. 
 
Abbreviations: EGFR, epidermal growth factor receptor; eIF4E, eukaryotic translation 
initiation factor complex 4E; 4E-BP, 4E-binding protein; mTOR, mammalian target of 
rapamycin; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide; 
NSCLC, non-small cell lung cancer; pS6, phospho-S6 ribosomal protein; TKI, tyrosine 
kinase inhibitor. 
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1. Introduction 
Somatic mutants of the epidermal growth factor receptor (EGFR), HER2, 
KRAS, BRAF, PIK3CA, and EML4-ALK of non-small cell lung cancers (NSCLCs) are 
viewed as targets of anti-cancer agents [1]. Of tumors in 52 East Asian never-smokers 
with lung adenocarcinomas, 78.8% harbored EGFR mutations, 5.8% (three) 
EML4-ALK fusions, 3.8% (two) HER2 mutations, and 1.9% (one) a KRAS mutation. 
Only 9.6% (five of 52) tumors did not harbor any of these known oncogenic driver 
mutations [2]. Never-smokers with NSCLC could be divided into four distinct 
genotypic groups based on genetic profiling of three major oncogenes (EGFR, 
EML4-ALK, and KRAS), yielding unique and non-overlapping subsets of patients with 
lung cancer who exhibited different therapeutic responses and survival outcomes [3]. 
The “Biomarker-integrated approaches of targeted therapy for lung cancer elimination” 
(BATTLE) program of personalized medicine has been recently developed [4]. Adaptive 
randomization was successfully used to assign NSCLC patients to the treatment offering 
the greatest potential benefit, based on the markers of prospectively biopsied tumors. 
Moreover, EGFR mutations and EML4-ALK gene rearrangements in NSCLC have been 
established as real molecular targets from the clinical studies [5]. Thus, it is important to 
treat patients with reference to their genetic profiles to determine whether patients can 
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benefit from specifically targeted therapies. 
EGFR mutations are more frequently observed in females, non-smokers, and 
adenocarcinoma patients, especially in Asian populations, wherein the mutation rate is 
30–50% [6]. The EGFR tyrosine kinase inhibitors (TKIs), erlotinib and gefitinib, 
improved progression-free survival in patients with NSCLC harboring EGFR mutations 
[7-11]. The majority of EGFR mutant lung cancers initially sensitive to EGFR-TKI 
become resistant to these agents within 1 year. Some possible mechanisms for 
acquisition of resistance have been identified, the most common being development of 
an EGFR T790M “gatekeeper” mutation in about 50% of cases [12][13]. Although 
clinical work seeking to overcome resistance acquired via T790M has been conducted, 
no generally accepted therapy has been established [14]. 
The mammalian target of rapamycin (mTOR) is located downstream of EGFR 
and plays a major role in regulation of protein translation, cell growth, and metabolism 
[15-18]. Alterations in the mTOR signaling pathway are common in cancer patients and 
mTOR is being actively explored as a therapeutic target [17]. Inhibition of mTOR by 
targeting agents causes G1 cell-cycle arrest mediated by inactivation of phospho-S6 
ribosomal protein (pS6) and hypophosphorylation of 4E-BP1 [16]. Everolimus is an 
orally administered rapamycin analog showing anticancer effects on renal cell 
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carcinoma and pancreatic neuroendocrine tumors [17]. Furthermore, in preclinical 
studies, everolimus showed anticancer effects in various cancer cell lines and xenograft 
models, including lung cancer [16]. However, the effect of mTOR inhibitors on NSCLC 
harboring EGFR mutations remains unclear. In our present study, we investigated the 
preclinical efficacy of everolimus in NSCLC harboring EGFR mutations. Our findings 
suggest that everolimus might be effective for NSCLC by the inhibiting tumor 
angiogenesis. 
 
2. Materials and Methods 
2.1. Cell lines and mouse model 
PC-9 is a lung adenocarcinoma cell line that has an in-frame deletion mutation at exon 
19 of EGFR and amplification of the EGFR gene. We used RPC-9 cells with the T790M 
mutation of EGFR that were 400-fold more resistant to gefitinib than parental PC-9 
cells [19]. The RPC-9 cell line was established in our laboratory by continuously 
exposing the PC-9 cell line to gefitinib. H3255 is a lung adenocarcinoma cell line that 
has a L858R point mutation at exon 21 of EGFR and amplification of the EGFR gene. 
A549 cells harbor wild-type EGFR. The cell lines were cultured in RPMI-1640 with 
10% (v/v) fetal bovine serum and 1% (w/v) penicillin/streptomycin in a tissue culture 
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incubator at 37˚C under 5% (v/v) CO2. 
We generated transgenic mice expressing the L858R mutation of EGFR driven 
by the SP-C promoter [20]. In the absence of treatment, these transgenic mice 
developed atypical adenomatous hyperplasia at 4 weeks of age and adenocarcinoma at 6 
to 7 weeks of age, and died from tumor progression at 25 to 40 weeks. The transgenic 
mice were randomly assigned to two groups that received either vehicle alone or 
everolimus (10 mg/kg/day) from 5 to 20 weeks of age. Vehicle and everolimus were 
administered once a day, five times a week, by gavage. Body weights were determined 
weekly. All mice were killed at 20 weeks of age and the number of superficial left lung 
tumors per mouse (with long axes exceeding 1 mm) was counted. The right lungs were 
used for protein extracts. To evaluate the efficacy of everolimus in terms of survival, 
mice were treated with oral everolimus (10 mg/kg/day) or vehicle alone from 5 weeks 
of age until death. All experiments involving animals were performed under the 
auspices of the Institutional Animal Care and Research Advisory Committee at the 
Department of Animal Resources, Okayama University Advanced Science Research. 
2.2 Sensitivity test 
Everolimus was the kind gift of Novartis. Drug sensitivity was evaluated using the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay [21]. The 
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cells were added to wells of 96-well plates at a density of 2,000 cells per well and 
exposed continuously to the drug for 96 h. The reason for which MTT assay was done 
with 96 h of drug incubation was that our previous study showed the cell viability assay 
with 96 h drug exposure could replace standard human clonogenic assay in evaluating 
the effects of anticancer agents [22]. The 50% inhibitory concentration (IC50) of 
everolimus was determined by plotting the logarithm of drug concentration versus the 
proportion of survivors. Each assay was performed in triplicate or quadruplicate. 
2.3. Immunoblotting 
Protein extracts were prepared from crushed tissue samples that had been suspended in 
lysis buffer (1% [v/v] Triton X-100, 0.1% [w/v] SDS, 50 mM Tris-HCl [pH 7.4], 150 
mM NaCl, 1 mM EDTA, 1 mM EGTA, 10 mM β-glycerol phosphate, 10 mM NaF, and 
1 mM Na-orthovanadate) containing protease inhibitors (Roche Diagnostics, Basel, 
Switzerland) and centrifuged at 15,000 rpm for 20 min at 4°C. After quantification 
using a Bio-Rad (Bio-Rad, Hercules, CA) protein assay, ~50 μg of protein were 
subjected to 5–15% SDS-PAGE (Bio-Rad) and then transferred to nitrocellulose 
membranes. Specific proteins were detected by the enhanced chemiluminescence assay 
(GE Healthcare, Buckinghamshire, UK) using antibodies (from Cell Signaling unless 
otherwise indicated) against EGFR (1:1,000 dilution), mTOR (1:1,000 dilution), AKT 
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(1:1,000 dilution), MAPK (1:1,000 dilution), PI3K (1:5,000 dilution; Upstate), S6, 
4E-binding protein (4E-BP) (1:1,000 dilution), pEGFR (1:1,000 dilution), pmTOR 
(1:1,000 dilution), pAKT (1:1,000 dilution), pMAPK (1:1,000 dilution), pS6 (1:1,000 
dilution), p4E-BP (1:1,000 dilution),-actin (1:1,000 dilution),  Beclin1 (1:1,000 
dilution), ATG5 (1:1,000 dilution), ATG7 (1:1,000 dilution), LC3B (1:1,000 dilution), 
PARP (1:1,000 dilution), and cleaved PARP (1:1,000 dilution). The secondary 
antibodies used were anti-rabbit and anti-mouse IgG (horseradish peroxidase-linked, 
species-specific whole antibodies; GE Healthcare), both of which were used at a 1:5,000 
dilution. 
2.4. Immunohistochemistry 
Formalin-ﬁxed parafﬁn-embedded tissue blocks of samples were cut to a thickness of 5 
m, placed on glass slides, and deparafﬁnized in xylene and a graded series of alcohol 
baths for 10 minutes. The sections were incubated in 10 mmol/L sodium citrate buffer, 
pH 6.0, for 10 minutes in a 95°C water bath. Endogenous peroxidase was then blocked 
with 0.3% (v/v) hydrogen peroxide in methanol. The slides were rinsed with TBS 
containing 0.1% (v/v) Tween 20 and blocked with normal goat serum for 60 minutes. 
The sections were incubated with a 1:200 dilution of anti-CD31 antibody (DIA310; 
Dianova) overnight at 4°C. The sections were next incubated with biotinylated 
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anti-rabbit antibodies and an avidin-biotinylated horseradish peroxidase conjugate for 
10 minutes (LSAB 2 Kit, Dako Cytomation) and then reacted with 
3,3’-diaminobenzidine. The three areas containing the highest numbers of stained cells 
within a section were selected for histological quantitation by microscopy at 400-fold 
magnification. 
2.5. Statistical analysis 
Statistical analysis was performed using the SPSS Base System
TM
 and Advanced 
Statistics
TM
 programs (SPSS, Chicago, IL). Group differences were compared using 
Student’s t-test. Survival time was deﬁned as the period from initiation of treatment to 
death. Overall survival curves were calculated using the Kaplan–Meier method. 
P-values ≤ 0.05 were considered to be statistically significant. 
 
3. Results 
3.1. Everolimus was effective regardless EGFR mutation status. 
Sensitivity to everolimus of lung cancer cell lines was examined at first. 
Everolimus exhibited similar efficacy on A549 cells (EGFR wild-type), H3255 cells 
(with the L858R mutation), PC-9 cells (with an exon 19 deletion mutation) and RPC-9 
cells (with both the exon 19 deletion mutation and the T790M mutation). The curves of 
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concentration versus surviving fraction were similar and all IC50s were around 0.01 M 
(Figure 1A, 1B). 
3.2. Everolimus suppressed pmTOR and pS6. 
Next, effect of everolimus on EGFR-related signals was examined using 
immunoblotting. pmTOR and pS6 in H3255 cells were suppressed by treatment with 
everolimus, whereas pAKT increased in level, presumably due to negative feedback 
from mTOR inhibition (Figure 1C). Similar results were obtained in PC-9 and RPC-9 
cells (Supplemental figure 1). However, in Figure 1C, both pS6 and mTOR levels were 
increased with increasing concentrations of everolimus. Thus, high dose of everolimus 
might increase pS6 and pmTOR as a result of negative feedback from AKT or mTORC2 
[23, 24]. Furthermore, everolimus had no effect on p4E-BP (Figure 1C, Supplemental 
figure 1). Although rapamycin decreased p4E-BP levels in NSCLC lines [25], 
everolimus had a variety of effects (increase, decrease or no change) on p4E-BP, 
dependent on treatment dose and duration [18]. A matter of degree of AKT activation by 
inhibiting mTOR might cause such results [24, 25]. 
3.3. The lung tumors in EGFR transgenic mice responded to everolimus. 
Firstly, proteins downstream of EGFR were evaluated in transgenic mice. 
Figure 2A showed that pmTOR, pS6 and p4E-BP were overexpressed. Thus, the mTOR 
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might be a therapeutic target in EGFR transgenic mouse models although mTOR is not 
the only protein downstream EGFR to be activated (Figure 1C, 2A). 
Secondary, antitumor effect of everolimus on EGFR transgenic mice which 
received either everolimus (10 mg/kg/day) or vehicle from 5 to 20 weeks of age (15 
weeks-treatment) was evaluated. The mean numbers (± SD) of superficial lung tumors 
(of long axis exceeding 1 mm) in the everolimus-treated and control group were 1.9 ± 
0.9 (n = 14) and 9.4 ± 3.2 (n = 13) (Student’s t-test, p<0.001), respectively (Figure 2B). 
Hematoxylin-eosin (H.E.) staining revealed that everolimus prevented progression of 
lung tumors (Figure 3A). pS6 was suppressed during everolimus treatment, although the 
pmTOR and p4E-BP levels were similar (Figure 3B). When the mice having more 
advanced lung tumors at age of 15 weeks were treated with everolimus (10 mg/kg/day) 
or vehicle for one week, pS6 and pmTOR expressions were decreased and p4E-BP 
expression was similar in the everolimus-treated mice compared with the vehicle-treated 
mice (Supplemental figure 2). In this situation, the tumors did not respond to one 
week-treatment with everolimus (data not shown). These results suggest that treatment 
duration and timing of administration of everolimus may affect the proteins downstream 
of EGFR. 
Thirdly, we treated the transgenic mice with everolimus (10 mg/kg/day) or 
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vehicle for 5 weeks. They had early (at age of 5 weeks) or advanced (at age of 12 
weeks) lung tumors and received either drug from 5 to 10 weeks of age (n =4 for 
vehicle and n = 7 for everolimus) or from 12 to 17 weeks (n = 3 for vehicle and n = 4 
for everolimus), respectively. The lung tumors in the sacrificed mice at 10 weeks of age 
and at 17 weeks of age responded to everolimus (Supplemental figures 3 and 4, 
respectively). 
3.4. Everolimus prolonged survival in EGFR transgenic mice. 
Subsequently, efficacy of everolimus on survival of EGFR transgenic mice was 
evaluated. The median survival time of the everolimus-treated group (58.0 weeks) was 
significantly longer than that of the vehicle group (31.2 weeks) (logrank test, p<0.001) 
(Figure 4A). The body weights of the everolimus-treated and vehicle groups did not 
significantly differ (Figure 4B). No apparent adverse event was noted in 
everolimus-treated mice.  
3.5. Everolimus inhibited angiogenesis. 
Finally, mechanisms of the anti-tumor effect of everolimus on EGFR-driven 
tumors were examined. Treatment with mTOR inhibitors was reported to induce 
autophagy and apoptosis [26-30]. The expression levels of Beclin 1, ATG5, ATG7, 
LC3B, and PARP in everolimus-treated H3255 cells are shown in Figure 5A. Cleaved 
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PARP was noted, and a cell transition from LC3B-I to LC3B-II observed. Thus, 
apoptosis and autophagy seemed to occur in vitro. Next, proteins expressed in the lungs 
of transgenic mice are shown in Figure 5B. Unexpectedly, neither LC3B-II status nor 
the level of cleaved PARP increased in everolimus-treated tumors compared with 
vehicle-treated tumors, although the experiment was performed several times. As the 
effects of everolimus in transgenic mice did not seem to be mainly attributable to 
apoptosis or autophagy, we next evaluated angiogenesis in these mice. 
Immunohistochemical staining of CD31 revealed that 15 weeks-treatment of 
everolimus inhibited angiogenesis in lung tumors of transgenic mice (Figure 6A). The 
mean numbers (± SE) of CD31- positive cells in the everolimus-treated and control 
groups (3 fields/lung sections of 4 mice, each) were 23.1 ± 6.9 and 72.2 ± 4.2, 
respectively (Student’s t-test, p<0.05) (Figure 6B). We performed another experiment, 
in which the mice were treated with vehicle alone (n = 3) or everolimus (10 mg/kg/day, 
n = 3) from 5 to 10 weeks of age and were sacrificed at 10 weeks of age. The mean 
numbers (± SE) of CD31- positive cells in the everolimus-treated and control groups 
were 34.8 ± 2.1 and 70.3 ± 2.0, respectively (Student’s t-test, p<0.05) (supplemental 
figure 5). Two different treatment durations (15 and 5 weeks) suppressed the 
angiogenesis. 
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4. Discussion 
We found that everolimus was similarly efficacious, in vitro, on cells harboring various 
EGFR mutations. The EGFR-tyrosine kinase inhibitor resistance-related T790M 
secondary mutation seemed to be neutralized by everolimus (Figure 1B). In addition, 
everolimus suppressed lung tumors in transgenic mice expressing the L858R mutation 
of EGFR and prolonged the overall survival of these mice. 
Signaling pathways of AKT/mTOR that include S6, 4E-BP, or the eukaryotic 
translation initiation factor complex 4E (eIF4E), have been reported to be associated 
with prognosis of NSCLC. Anagnostou et al. found that a high mTOR protein level 
were an independent favorable prognostic factor for surgically resected adenocarcinoma 
of the lung [31]. Yoshizawa et al. found that expression of peIF4E, in addition to pAKT, 
predicted poor prognosis of surgically resected NSCLC but pmTOR expression was not 
a prognostic factor [32]. Dhillion et al. reported that high-level mTOR expression 
significantly predicted poor survival in resected stage IA-IIB NSCLC patients [33]. Liu 
et al. found that the levels of mTOR, pmTOR, pAKT, and pS6 in surgically resected 
primary NSCLC were higher than in the wild-type lung [34]. In this study, overall 
survival was significantly shorter in cases positive for pmTOR, pPDK1, and pS6. Thus, 
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although AKT/mTOR-related proteins are often overexpressed in NSCLC, the 
prognostic implications remain unclear. In our EGFR transgenic mice, mTOR and 
4E-BP were activated (Figure 2A). Everolimus suppressed pmTOR and pS6 but not 
p4E-BP, and increased pAKT (via negative feedback) in vitro (Figure 1C). Also, 
everolimus suppressed pS6 but not pmTOR and p4E-BP in vivo (Figure 3B). 
Conceivably, everolimus may act on different signaling pathways in vitro and in vivo. 
Our results using transgenic mice suggest that marked suppression of pS6 by 
everolimus might be important in this respect. 
Apoptosis and autophagy were enhanced in response to exposure to mTOR 
inhibitors [26-30]. Tumor inhibition mediated by mTOR inhibitors seemed to involve 
antiangiogenic activity, correlating with impaired vascular endothelial growth factor 
(VEGF) production and blockage of VEGF-induced vascular endothelial cell 
stimulation by enhancement of hypoxia inducible factor-1 (HIF-1) degradation [17, 35]. 
Although apoptosis and autophagy were not induced in everolimus-treated EGFR 
transgenic mice (Figure 5B), angiogenesis was suppressed (Figure 6). Indeed, even 
EGFR-TKIs induced both apoptosis and autophagy in EGFR-mutated NSCLC cells in 
vitro [36, 37]. However, whether autophagy causes cancer cell death or confers a 
survival advantage on tumor cells under stressful conditions remains unclear [37, 38]. 
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Everolimus may control autophagy in cancer cells although we do not know why the in 
vitro and in vivo data differ. Recently, two mTOR inhibitors (temsirolimus and 
everolimus) were shown to suppress the growth of EGFR mutant lung cancer cells in 
vitro and in vivo [39]. Also, temsirolimus markedly inhibited cell angiogenesis in both 
PC-9- and EGFR-TKI-resistant (PC-9/HGF) xenograft tumors. We found that 
everolimus exhibited similar efficacy when added to cultures of four EGFR-TKI- 
sensitive and -insensitive cells in vitro, and everolimus suppressed tumor growth and 
prolonged survival in EGFR-mutated transgenic mice. Thus, our present data support 
their findings. Although some reports have shown that combination of an mTOR 
inhibitor with EGFR-TKI was an effective therapy [40-42], the possible value of 
everolimus monotherapy of EGFR-mutated lung cancer cells has been shown only by 
Ishikawa et al. [39] and us. A strength of our study is that we first showed that lung 
tumors in EGFR-transgenic mice were sensitive to everolimus, and the drug prolonged 
survival. However, it is very unlikely that EGFR mutant lung cancer will ever be treated 
without the presence of an EGFR-TKI [14]. Naturally, gefitinib was effective for the 
EGFR transgenic mice [20]. The median survival in the mice (n = 13) treated with 
gefitinib was more than 100 weeks (Supplemental figure 6). EGFR mutant lung cancer 
patients who were refractory to EGFR-TKIs might have benefits from the treatment 
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with everolimus. Thus, a weakness of our study is that we could not discover whether 
EGFR-TKI-resistant transgenic mice with a T790M secondary mutation were also 
sensitive to everolimus alone because we did not have such mice. 
In a phase II study [43], advanced NSCLC patients, who had undergone two or 
fewer prior chemotherapy regimens, one platinum-based (stratum 1); or both 
chemotherapy and EGFR-TKI treatment (stratum 2); received everolimus (10 mg/day). 
Eighty-five patients were enrolled, 42 in stratum 1 and 43 in stratum 2. The overall 
response rate was 4.7% (7.1% in stratum 1; 2.3% in stratum 2) and the overall disease 
control rate 47.1%. Only 11 cases were evaluated for EGFR mutations and none was 
detected. Although everolimus showed modest clinical activity when given to heavily 
pretreated patients with advanced-stage NSCLC, the clinical activity of everolimus in 
NSCLC patients harboring EGFR mutations should be further evaluated. In conclusion, 
our present study suggested that everolimus might be effective to treat EGFR-mutated 
lung cancer and had an indirect effect on tumor formation by inhibiting angiogenesis. 
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Figure legends 
Figure 1 
A) B) Sensitivity of lung cancer cell lines to everolimus. Everolimus was similarly 
efficacious on H3255 cells (with the L858R mutation), PC-9 cells (with an exon 19 
deletion mutation), RPC-9 cells (with the exon 19 deletion mutation and the T790M 
mutation), and A549 cells (EGFR wild-type). Bars indicate SD. 
C) Western blotting for EGFR, AKT, MAPK, PI3K, mTOR, S6, 4E-BP, and -actin in 
H3255 cells. The cells were treated with various concentrations of everolimus for 6 
h. pmTOR and pS6 were suppressed by treatment with everolimus, whereas the 
pAKT level was increased, presumably due to negative feedback from mTOR 
inhibition. 
 
Figure 2 
A) Western blotting for EGFR, mTOR, S6, 4E-BP, and -actin in the lungs of 20 
week-old EGFR transgenic and wild-type mice. Proteins downstream of EGFR, 
including mTOR, were activated. 
B) The numbers of superficial lung tumors (long axis exceeding 1 mm) in the 
everolimus-treated and control groups were 1.9 ± 0.9 and 9.4 ± 3.2 (Student’s t-test, 
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p<0.001), respectively. Bars indicate SD. 
 
Figure 3 
A) Hematoxylin-eosin (H.E.) staining revealed that everolimus suppressed lung tumors 
in EGFR transgenic mice. 
B) Western blotting for EGFR, AKT, MAPK, PI3K, mTOR, S6, 4E-BP, and -actin in 
the lungs of transgenic mice. pS6 was suppressed during everolimus treatment. 
 
Figure 4 
A) The median survival time in the everolimus-treated group was significantly longer 
than that in the vehicle group (log-rank test, p<0.001).  
B) There was no significant difference in the body weights of the everolimus-treated 
and vehicle-treated group. Bars indicate SE. 
 
Figure 5 
Expression of proteins associated with apoptosis and autophagy. 
A) Western blotting for Beclin 1, ATG5, ATG7, LC3B, and PARP in everolimus-treated 
H3255 cells. Cleaved PARP, and the transition from LC3B-I to LC3B-II, were observed. 
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B) Western blotting for Beclin 1, ATG5, ATG7, LC3B, and PARP in transgenic mice. 
Neither the LC3B-II state, nor cleaved PARP, increased in everolimus-treated compared 
with vehicle-treated tumors. 
 
Figure 6 
Evaluation of angiogenesis in transgenic mice 
A) Immunohistochemical staining of CD31 revealed that everolimus inhibited 
angiogenesis in lung tumors of EGFR transgenic mice.  
B) The numbers of CD31-positive cells in the everolimus-treated and vehicle-treated 
group were 23.1 ± 6.9 and 72.2 ± 4.2, respectively (Student’s t-test, p<0.05). Bars 
indicate SE. 
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Supplemental Figure legends 
1. Western blotting for EGFR, AKT, MAPK, PI3K, mTOR, S6, 4E-BP, and -actin in 
PC-9 cells (with an exon 19 deletion mutation) and RPC-9 cells (with the exon 19 
deletion mutation and the T790M mutation). The cells were treated with 2 M of 
everolimus for 6 h. pmTOR and pS6 were suppressed by treatment with everolimus. 
 
2. The transgenic mice having lung tumors at age of 15 weeks were treated with 
everolimus (10 mg/kg/day) or vehicle for one week. pS6 and pmTOR expressions were 
decreased and p4E-BP expression was similar in the everolimus-treated mice compared 
with the vehicle-treated mice. 
 
3. The transgenic mice were treated with vehicle alone (n = 4) or everolimus (10 
mg/kg/day, n = 7) from 5 to 10 weeks of age. All the mice were sacrificed at 10 weeks 
of age. The tumors in mice treated with everolimus had anti-tumor effect. 
 
4. The transgenic mice were treated with vehicle alone (n = 3) or everolimus (10 
mg/kg/day, n = 4) from 12 to 17 weeks of age. All the mice were sacrificed at 17 weeks 
of age. The tumors in mice treated with everolimus had anti-tumor effect. 
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5. Evaluation of angiogenesis in transgenic mice with vehicle alone (n =3) or 
everolimus (10 mg/kg/day, n = 3) from 5 to 10 weeks of age. 
A) Immunohistochemical staining of CD31 revealed that everolimus inhibited 
angiogenesis in lung tumors of EGFR transgenic mice (X 400). 
B）The numbers of CD31-positive cells in the everolimus-treated and vehicle-treated 
group (3 fields/lung sections of 3 mice, each) were 34.8 ± 2.1 and 70.3 ± 2.0, 
respectively (Student’ s t-test, p<0.05). Bars indicate SE. 
 
6. The survival curve of the EGFR transgenic mice treated with gefitinib.  
The median survival in the mice (n = 13) treated with gefitinib was more than 100 
weeks. 
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